The Australian government is moving to block a $387.2m takeover deal of Mayne Pharma by US company Cosette Pharmaceuticals, citing a “national security” need to protect “critical medical supply chains.”
Mayne Pharma’s business, which focuses on therapeutic areas like women’s health, dermatology, pain and infectious diseases, is mainly in the
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
